292 related articles for article (PubMed ID: 21876474)
1. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
[TBL] [Abstract][Full Text] [Related]
2. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
6. Influence of cytomegalovirus disease in outcome of solid organ transplant patients.
Linares L; Sanclemente G; Cervera C; Hoyo I; Cofán F; Ricart MJ; Pérez-Villa F; Navasa M; Marcos MA; Antón A; Pumarola T; Moreno A
Transplant Proc; 2011; 43(6):2145-8. PubMed ID: 21839217
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of cytomegalovirus infection after pancreas transplantation.
Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC
Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
9. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
11. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
13. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
Stratta RJ; Alloway RR; Lo A; Hodge EE;
Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
Kirklin JK; Naftel DC; Levine TB; Bourge RC; Pelletier GB; O'Donnell J; Miller LW; Pritzker MR
J Heart Lung Transplant; 1994; 13(3):394-404. PubMed ID: 8061014
[TBL] [Abstract][Full Text] [Related]
15. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
[TBL] [Abstract][Full Text] [Related]
16. Post-renal transplant cytomegalovirus infection: study of risk factors.
Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
